6 recruiting, 4 active not recruiting, 3 withdrawn, 2 completed. 18 Phase 1, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Recruiting 6, Active not recruiting 4, Withdrawn 3, Completed 2, Terminated 2, Suspended 1 |
| Phase 2 | 13 | Active not recruiting 4, Recruiting 4, Withdrawn 3, Terminated 2 |
Follow tafasitamab: new trials by email Literature Review of tafasitamab trials Research Report on tafasitamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders Tafasitamab, Fludarabine phosphate, Cyclophosphamide - Autoimmune Disorders, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 47 | 2024-07-31 | 2026-11-03 |
| Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma Zanubrutinib, Tafasitamab - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Alvaro Alencar, MD | 27 | 2024-05-03 | 2026-09-21 |
| Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy - Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder | Phase 1 | Suspended | City of Hope Medical Center | 27 | 2024-02-19 | 2025-11-13 |
| Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 27 | 2023-10-02 | 2025-11-06 |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia Tafasitamab - ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse | Phase 1 / Phase 2 | Recruiting | University Hospital Tuebingen | 20 | 2023-03-08 | 2026-02-05 |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 33 | 2023-01-26 | 2026-10-30 |
| Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients Tafasitamab, Lenalidomide - Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Incyte Corporation | 53 | 2022-07-19 | 2026-01-16 |
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma Tafasitamab, Lenalidomide - CNS Lymphoma, Primary Central Nervous System Lymphoma | Phase 1 / Phase 2 | Recruiting | James Rubenstein | 35 | 2022-06-08 | 2026-07-14 |
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. Tazemetostat, Tafasitamab, Lenalidomide - Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | Phase 1 / Phase 2 | Withdrawn | Epizyme, Inc. | 2021-12-22 | 2023-08-15 | |
| Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma CC-220, Polatuzumab vedotin, Rituximab - Lymphoma, B-Cell | Phase 1 / Phase 2 | Withdrawn | Celgene | 2021-10-10 | 2021-10-05 | |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) tafasitamab, parsaclisib - Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 54 | 2021-09-16 | 2026-02-04 |
| To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) tafasitamab, lenalidomide, parsaclisib - Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Incyte Biosciences Japan GK | 72 | 2020-12-15 | 2026-10-21 |
| Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Selinexor, Rituximab, Bendamustine - Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | Karyopharm Therapeutics Inc | 2020-11-18 | 2025-10-03 | |
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL Tafasitamab, Tafasitamab plus lenalidomide - Diffuse Large B-cell Lymphoma | Phase 1 | Completed | MorphoSys AG | 66 | 2019-12-11 | 2024-10-16 |
| A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) CC-99282, Rituximab, Obinutuzumab - Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Active not recruiting | Celgene | 438 | 2019-05-20 | 2026-02-19 |
| Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia XmAb5574 - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Completed | Xencor, Inc. | 27 | 2010-09-01 | 2014-04-21 |
Lymphoma, Large B-Cell, Diffuse (7) · Recurrence (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Non-Hodgkin (4) · Bronchiolitis Obliterans Syndrome (2) · Lymphoma, B-Cell (2) · Lymphoma, Mantle-Cell (2) · Autoimmune Diseases (1) · Graft vs Host Disease (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Lymphoma (1)
Celgene (2) · Incyte Corporation (2) · Alvaro Alencar, MD (1) · City of Hope Medical Center (1) · Epizyme, Inc. (1) · Incyte Biosciences Japan GK (1) · James Rubenstein (1) · Karyopharm Therapeutics Inc (1) · M.D. Anderson Cancer Center (1) · MorphoSys AG (1) · OHSU Knight Cancer Institute (1) · Paolo Caimi, MD (1) · Pfizer (1) · University Hospital Tuebingen (1) · University of Washington (1)
United States (16) · Austria (5) · France (5) · Spain (5) · Belgium (4) · Italy (4) · South Korea (4) · Germany (3) · Czechia (2) · Israel (2) · Japan (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · Canada (1)
Alvaro Alencar, MD (1) · Amandeep Salhotra (1) · Chitra Hosing, MD (1) · Farrukh Awan, MD (1) · Ian W Flinn, MD, PhD (1) · James Rubenstein, MD, PhD (1) · John C Byrd, MD (1) · Oliver Manzke, MD (1) · Paolo Caimi, MD (1) · Peter Lang, Prof. (1) · Stephen D. Smith (1)
PMID 25301708, PMID 37369099, PMID 39319495, PMID 40802906, PMID 41563911
2018 (1), 2023 (1), P30CA033572 (1)